These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 2332982)
1. Propafenone kinetics in the horse. Comparative analysis of compartmental and noncompartmental models. Puigdemont A; Riu JL; Guitart R; Arboix M J Pharmacol Methods; 1990 Apr; 23(2):79-85. PubMed ID: 2332982 [TBL] [Abstract][Full Text] [Related]
2. Tissue distribution of propafenone in the rat after intravenous administration. Fernández J; Lligoña L; Puigdemont A; Guitart R; Riu JL; Arboix M Eur J Drug Metab Pharmacokinet; 1991; 16(1):23-7. PubMed ID: 1936057 [TBL] [Abstract][Full Text] [Related]
3. Use of propafenone for conversion of chronic atrial fibrillation in horses. De Clercq D; van Loon G; Tavernier R; Verbesselt R; Deprez P Am J Vet Res; 2009 Feb; 70(2):223-7. PubMed ID: 19231955 [TBL] [Abstract][Full Text] [Related]
4. Bioavailability of an extemporaneous suspension of propafenone made from tablets. Olguín HJ; Pérez CF; Pérez JF; Mendiola BR; Portugal MC; Chávez JB Biopharm Drug Dispos; 2006 Jul; 27(5):241-5. PubMed ID: 16586461 [TBL] [Abstract][Full Text] [Related]
5. Intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response. Ito S; Gow R; Verjee Z; Giesbrecht E; Dodo H; Freedom R; Tonn GR; Axelson JE; Zalzstein E; Rosenberg HC; Koren G J Clin Pharmacol; 1998 Jun; 38(6):496-501. PubMed ID: 9650538 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315 [TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Brian Houston J; Oosterhuis B; Bjerrum OJ; Grynkiewicz G; Alder J; Rowland M; Garner C Eur J Pharm Sci; 2011 Jun; 43(3):141-50. PubMed ID: 21540108 [TBL] [Abstract][Full Text] [Related]
9. Influence of hepatic dysfunction on the pharmacokinetics of propafenone. Lee JT; Yee YG; Dorian P; Kates RE J Clin Pharmacol; 1987; 27(5):384-9. PubMed ID: 3693582 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group. Zoble RG; Kirsten EB; Brewington J Clin Pharmacol Ther; 1989 May; 45(5):535-41. PubMed ID: 2721109 [TBL] [Abstract][Full Text] [Related]
11. [HPLC determination of diprafenone and its active metabolite 5-hydroxydiprafenone in human plasma]. Zhong D; Blume H Pharmazie; 1994 Jan; 49(1):38-41. PubMed ID: 8140128 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of propafenone in the dog after single-dose intravenous administration. Puigdemont A; Lligoña LL; Arboix M; de Mora F; Fernandez J J Vet Pharmacol Ther; 1987 Dec; 10(4):351-3. PubMed ID: 3437498 [No Abstract] [Full Text] [Related]
13. Prediction of the disposition of propafenone in humans and dogs from pharmacokinetic parameters in other animal species. Puigdemont A; Guitart R; de Mora F; Arboix M J Pharm Sci; 1991 Dec; 80(12):1106-9. PubMed ID: 1815066 [TBL] [Abstract][Full Text] [Related]
14. Species scaling of propafenone disposition and concentration--time relationships among eight mammalian species. Puigdemont A; Ramis J; Guitart R; Arboix M J Pharm Sci; 1993 Nov; 82(11):1126-9. PubMed ID: 8289126 [TBL] [Abstract][Full Text] [Related]
15. Nonlinear kinetics of propafenone metabolites in healthy man. Vozeh S; Haefeli W; Ha HR; Vlcek J; Follath F Eur J Clin Pharmacol; 1990; 38(5):509-13. PubMed ID: 2379537 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of marbofloxacin in mature horses after single intravenous and intramuscular administration. Carretero M; Rodríguez C; San Andrés MI; Forés P; de Lucas JJ; Nieto J; Waxman S; San Andrés MD; González F Equine Vet J; 2002 Jul; 34(4):360-5. PubMed ID: 12117107 [TBL] [Abstract][Full Text] [Related]
17. Comparative bioavailability of propafenone after administration of a magistral suspension vs. commercial tablets in healthy volunteers. Juárez Olguín H; Flores Pérez C; Ramírez Mendiola B; Barranco Garduño L; Sandoval Ramírez E; Flores Pérez J Arzneimittelforschung; 2009; 59(3):117-20. PubMed ID: 19402341 [TBL] [Abstract][Full Text] [Related]
18. A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode. Patel H; Ghoghari A; Bhatt C; Shah S; Jha A; Desai N; Srinivas NR Biomed Chromatogr; 2017 Oct; 31(10):. PubMed ID: 28261841 [TBL] [Abstract][Full Text] [Related]
19. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man. Trenk D; Wagner F; Sachs W; Jähnchen E Eur J Clin Pharmacol; 1989; 37(3):313-6. PubMed ID: 2612546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]